Most common adverse reactions (≥2%, pooled safety data across PRIME
and PRIME2)1
| ADVERSE REACTION | DUPIXENT 300 mg Q2W (n=152) % |
PLACEBO (n=157) % |
|---|---|---|
| Nasopharyngitisa | 5 | 2 |
| Conjunctivitisb | 4 | 1 |
| Herpes Infectionc | 3 | 0 |
| Dizzinessd | 3 | 1 |
| Myalgiae | 3 | 1 |
| Diarrhea | 3 | 1 |
aNasopharyngitis includes pharyngitis.
bConjunctivitis includes conjunctivitis and allergic conjunctivitis.
cHerpes infection includes oral herpes, genital herpes simplex, herpes zoster, and ophthalmic herpes zoster.
dDizziness includes dizziness postural, vertigo, and vertigo positional.
eMyalgia includes musculoskeletal pain and musculoskeletal chest pain.
DISCONTINUATION DUE TO ADVERSE EVENTS: 0% with DUPIXENT vs 3% with placebo1- Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment1
DUPIXENT attributes
and considerations1
NOT AN IMMUNOSUPPRESSANT
NO INITIAL LAB TESTING OR
ONGOING
LAB MONITORING,
according to Prescribing
Information
NO KNOWN DRUG-TO-DRUG
INTERACTIONS
- Not metabolized through the liver or excreted
through the kidneys
NO BOXED WARNING
Please see additional Warnings and
Precautions in the Prescribing Information and
Important Safety Information below.
SELECT IMPORTANT
SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT
Q2W, once every 2 weeks.
Dosage and administration
Thinking about prescribing DUPIXENT? Find the
information you need to get started.